All Updates

All Updates

icon
Filter
Earnings/results
Elevation Oncology misses analyst consensus; net losses narrow for Q2 2023
Precision Medicine
Aug 3, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Aug 3, 2023

Elevation Oncology misses analyst consensus; net losses narrow for Q2 2023

Earnings/results

  • Elevation Oncology reported a net loss per share of USD 0.37 in Q2 2023, missing analyst expectations by 15.6%. Net loss for the quarter decreased by 49.3% YoY to USD 10.1 million. Elevation Oncology is a clinical-stage company that does not generate any drug sales.

  • The company achieved a few milestones for the quarter, such as 1) highlighting first-in-human Phase I clinical data of SYSA1801 (EO-3021) and 2) completing public offering of common stock in June 2023, raising approximately USD 46.5 million in net proceeds.

  • Operating expenses for the quarter were USD 9.8 million (down 51.1% YoY). The decrease in operating expenses for Q2 2023 was mainly attributable to the reduction in R&D expenses (down 63.1% YoY), primarily due to the decrease in costs related to manufacturing clinical supply of seribantumab for use in the CRESTONE clinical trial. Further, administration costs for Q2 2023 was USD 3.8 million. 

  • Cash and cash equivalents stood at USD 107.9 million at the end of June 2023, increasing from USD 90.3 million in December 2022, which it claims is sufficient to operate until the second half of 2025.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.